Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.
Petek. M M; Sikiric. P P; Anic. T T; Buljat. G G; Separovic. J J; Stancic-Rokotov. D D; Seiwerth. S S; Grabarevic. Z Z; Rucman. R R; Mikus. D D; Zoricic. I I; Prkacin. I I; Sebecic. B B; Ziger. T T; Coric. V V; Turkovic. B B; Aralica. G G; Rotkvic. I I; Mise. S S; Hahn. V V
Key Findings
- Alloxan causes noticeable gastric lesions in rats and mice.
- Co‑administration of BPC‑157 (10 µg/kg or 10 ng/kg, i.p.) significantly reduces those lesions.
- The protective effect is seen in both rats and mice and persists over short (24 h) and longer (1‑2 weeks) periods.
- Both microgram and nanogram doses are effective, indicating high potency.
Practical Outcomes
- BPC‑157 may have strong stomach‑protective properties even at ultra‑low doses, suggesting potential use for ulcer or gut‑lining support. However, the data are from animal models with injectable dosing, so human protocols are not established. Enthusiasts should view this as promising but experimental, awaiting human safety and dosing studies before routine use.
Summary
In rats and mice, a chemical that mimics diabetes (alloxan) damages the stomach lining, but giving the peptide BPC‑157 at very tiny doses (either 10 µg/kg or 10 ng/kg) at the same time cuts down the damage. The protection works in both species and at both dose levels.
Abstract
A diabetogenic alloxan regimen produced lesions in all stomachs of treated animals, either rats (200 mg x kg(-1) s.c.) or mice (400 mg x kg(-1) i.p.). In control animals, the lesions, when developed (i.e. 24 h following application), appear to be quite sustained, and consistently present also after 1 or 2 weeks. The application of the pentadecapeptide BPC 157 (10 microg or 10 ng x kg(-1) i.p. coadministered together with alloxan) would significantly attenuate these lesions' appearance. This beneficial effect seems to be present in either rats or mice and in either of the tested intervals. Importantly, the beneficial effect seems to be shared by both microgram and nanogram regimens.
Study Information
pubmed
1999
10.1016/s0928-4257(99)00120-5